A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19
Sponsor: |
Gilead |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS9614 |
U.S. Govt. ID: |
NCT04292899 |
Contact: |
Allison Wolf: 212-342-4412 / aw2565@cumc.columbia.edu |
The purpose of this study is to test a medication to treat COVID-19 called remdesivir (RDV) that has not yet been approved by the FDA. If you choose to take part in this study, you will continue to receive the standard care for COVID-19. In addition, you will be randomized to either a 5-day or a 10-day treatment with RDV intravenously (by vein in the arm). You will be in this study for 28 days, or until you leave the hospital or clinic, whichever is earlier. This does not include the screening period which can last up to 3 days.
This study is closed
Investigator
Max O'Donnell, MD, MPH
Is the patient 12 years of age or older? |
Yes |
No |
Has the patient tested positive for COVID-19? |
Yes |
No |
Is the patient currently hospitalized and require medical care for COVID-19? |
Yes |
No |
Does the patient currently require mechanical ventilation? |
Yes |
No |